AI Article Synopsis
- A systematic review was conducted to assess the safety of the live rotavirus vaccine in infants who were exposed to biologic medications in utero, with a focus on anti-TNF and non-TNF biologics.* -
- Out of 7185 initial search results, 10 studies were included, covering over 300 instances of rotavirus vaccination in these infants, showing no significant increase in severe adverse events related to the vaccination.* -
- The findings suggest that the live rotavirus vaccine is likely safe for biologic-exposed infants, indicating potential for its administration with careful risk-benefit consideration.*
Article Abstract
Background: In infants that were exposed to biologics in utero, gastroenterology societal guidelines have either recommended against administration of the live rotavirus vaccine until 6-12 months of age or until serum biologic levels are undetectable. We performed a systematic review to evaluate the safety of rotavirus vaccination in biologic-exposed infants.
Methods: EMBASE, PubMed, Scopus, and Cochrane databases were searched from 2006 to 2024 for original data reporting on the safety of rotavirus vaccination in infants that were exposed to anti-tumor necrosis factors (TNFs) (ie, infliximab, adalimumab, golimumab, certolizumab) and non-TNF biologics (ie, vedolizumab, ustekinumab, rizankizumab, mirikizumab) in utero.
Results: A database search yielded 7185 screening results of which 10 studies met inclusion criteria. There were over 300 instances of rotavirus vaccination in biologic-exposed infants (n = 162 exposed to anti-TNFs, n = 142 exposed to non-TNF biologics). Biologic-exposed infants were not at an increased risk of severe adverse events or adverse events of any severity related to rotavirus vaccination.
Conclusions: Administration of the live rotavirus vaccine appears to be safe in biologic-exposed infants. As such, with careful examination of the risks and benefits, there may be a role for rotavirus vaccination in this population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ibd/izae220 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Significant abundance of bacterial flagellin and expression of its surface localized receptor toll-like receptor 5 and cytokine interleukin-22 in South African infants with poor oral rotavirus vaccine take.
Gut Pathog
January 2025
Diarrheal Pathogens Research Unit (DPRU), Department of Virology, Sefako Makgatho Health Sciences University, Ga-rankuwa, Pretoria, South Africa.
Bacterial flagellin, a potent intestinal innate immune activator, prevents murine rotavirus (RV) infection independent of adaptive immunity and interferons. The flagellin-induced immunity is mediated by Toll-like receptor (TLR5) and Nod-like receptor C4 (NLRC4), which elicit the production of interleukins 22 (IL-22) and IL-18, respectively. Here, we assessed whether a high abundance of flagellin at the time of vaccination would negatively affect the oral RV vaccine take.
View Article and Find Full Text PDFDerivation and validation of a clinical predictive model for longer duration diarrhea among pediatric patients in Kenya using machine learning algorithms.
BMC Med Inform Decis Mak
January 2025
Kenya Medical Research Institute- Center for Global Health Research (KEMRI-CGHR), P.O Box 1578-40100, Kisumu, Kenya.
Background: Despite the adverse health outcomes associated with longer duration diarrhea (LDD), there are currently no clinical decision tools for timely identification and better management of children with increased risk. This study utilizes machine learning (ML) to derive and validate a predictive model for LDD among children presenting with diarrhea to health facilities.
Methods: LDD was defined as a diarrhea episode lasting ≥ 7 days.
Effectiveness of monovalent rotavirus vaccine against hospital-attended rotavirus gastroenteritis among children in Uganda.
Vaccine
January 2025
Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address:
Background: The underlying causes for lower rotavirus vaccine effectiveness (VE) in high-child-mortality settings are not well understood. Uganda introduced the human monovalent G1P[8] rotavirus vaccine (Rotarix) in June 2018. We determined the effectiveness of Rotarix against rotavirus diarrhea requiring hospital care among Ugandan children.
View Article and Find Full Text PDFVaccination coverage in children up to 2 years old born in 2017 and 2018 in the municipalities of São Paulo and Campinas, Brazil: comparison of the results of a national survey and the National Immunization Program Information System.
Epidemiol Serv Saude
January 2025
Universidade de BrasÃlia, BrasÃlia, DF, Brazil.
Objective: To estimate and compare vaccination coverage among children born in 2017-2018 in São Paulo and Campinas, according to the Vaccination Coverage Survey (ICV 2020) and the National Immunization Program Information System (SI-PNI).
Methods: ICV 2020 analyzed vaccination card records. Coverage was calculated and compared to doses recorded on the SI-PNI, divided by the target population.
Rotavirus vaccine effectiveness and coverage among children younger than 5Â years old in Shanghai, China: A test-negative case control study.
Vaccine
January 2025
Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China; Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China. Electronic address:
Objectives: The number of post-marketing studies assessing the vaccine effectiveness (VE) of the Lanzhou lamb rotavirus vaccine (LLR, licensed in 2000 exclusively in China) and the oral human attenuated pentavalent rotavirus vaccine (RotaTeq, licensed in China in 2018) in China is limited.
Methods: A test-negative case-control study based on prospective surveillance was conducted among diarrhea patients aged 5Â years and younger at five hospitals in Shanghai, China. Cases and controls were defined based on the results of real-time fluorescent quantitative reverse transcription polymerase chain reaction (rRT-PCR) of fecal samples for rotavirus.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!